News
-
-
PRESS RELEASE
Following decisive advances and a significant improvement in its results in 2024, Amoéba is approaching 2025 with confidence and is getting closer to commercialising its first products
Amoéba achieves significant milestones in 2024, including strategic partnerships, financial improvements, and advancements in biocontrol and cosmetics. Financial statements show positive growth -
-
-
-
-
PRESS RELEASE
Amoéba confirms the extension of production capacity of its Chassieu site (France) to support its commercial deployment
Amoéba, an industrial greentech company specializing in microbiological solutions, extends production capacity at its Chassieu site. Commercial negotiations for 'AXPERA' products progressing -
-
PRESS RELEASE
Amoéba announces the initiation of coverage of its stock by Euroland Corporate with a target price of EUR 2.40
Amoéba announces Euroland Corporate's initiation of stock coverage with a Buy recommendation and a target price of €2.40 per share, aiming at over 150% potential upside. Amoéba focuses on natural microbiological solutions using amoebae -